USFDA inspections gather pace; Indian pharma companies equipped to handle disruptions
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)
India's G20 Presidency will focus on three main priorities: Health Emergencies Prevention, Preparedness and Response (One Health & AMR); Access and Availability to Affordable Medical Countermeasures (Vaccines, Therapeutics, and Diagnostics); and Digital Health
This DSIR recognition for company's in-house R&D Unit make it eligible for receiving funds for R&D purpose from various government departments and agencies
The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India
APAC to see a reduction in imported surgical robotics
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
The company was chosen for this transformative exercise due to its deep expertise in the healthcare vertical, coupled with its digital engineering and cloud capabilities, a vast partner network, and long-term relationship with the client
Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults
Subscribe To Our Newsletter & Stay Updated